Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
(NASDAQ:DNLI), Tividenofusp alfa BLA review process for accelerated approval for MPS II continues with productive engagement with the FDA; commercial launch preparations on track DNL126 Phase 1/2 study enrollment completed, supporting an accelerated approval path in MPS IIIA Two new regulatory applications submitted to initiate clinical studies with DNL628 (OTV:MAPT) for Alzheimer's disease and DNL952 […]